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ABSTRACT
It is currently known that estrogen plays an important role in breast cancer (BC) 
development, but the underlying molecular mechanism remains to be elucidated. 
Accumulating evidence has revealed important roles of microRNAs in various kinds 
of human cancers, including BC. In this study, we found that among the microRNAs 
regulated by estrogen, miR-124 was the most prominent downregulated miRNA. 
miR-124 was downregulated by estradiol (E2) treatment in estrogen receptor (ER) 
positive BC cells, miR-124 overexpression suppressed cell proliferation, migration and 
invasion in BC cells; while the suppression of miR-124 using Anti-miR-124 inhibitor 
had opposite cellular functions. Under the E2 treatment, miR-124 had stronger 
effect to inhibit cellular functions in MCF7 cells than that in MDA-MB-231 cells. In 
addition, we identified that ERα, but not ERβ, was required for E2-induced miR-124 
downregulation. Furthermore, AKT2, a known oncogene, was a novel direct target of 
miR-124. AKT2 expression levels were inversely correlated with miR-124 expression 
levels in human breast cancer specimens. AKT2 was overexpressed in BC specimens, 
and its expression levels were much higher in ERα positive cancer tissues than those 
ERα negative cancer tissues. Consistent with miR-124 suppression, E2 treatment 
increased AKT2 expression levels in MCF7 cells via ERα. Finally, overexpression of 
miR-124 in MCF7 cells significantly suppressed tumor growth and angiogenesis by 
targeting AKT2. Our results provide a mechanistic insight into a functional role of new 
ERα/miR-124/AKT2 signaling pathway in BC development. miR-124 and AKT2 may 
be used as biomarkers for ERα positive BC and therapeutic effect in the future.
INTRODUCTION
Breast cancer (BC) is one of the most common 
gynecological malignancies and estrogen receptor α (ERα) 
is expressed in about 75% of diagnosed breast tumors 
(ERα positive) [1, 2]. Growing evidence manifests that 
exposure to estrogens (estrone and estradiol) is an important 
determinant of BC risk, and ERα blockers have been widely 
used in clinic to treat BC [3, 4]. However, the expression 
of estrogen receptor β (ERβ), the other subunit of estrogen 
receptor, is reduced during tumorigenesis and is important 
in terminal differentiation of breast epithelial cells [5, 6]. 
Estrogen influences numerous cell signal pathways by 
activing ERα which is essential for the proliferation of a 
large subset of breast tumors [7–9]. Some reports have 
shown that estrogen could interfere with repair of mutations 
by speeding up the cell division, which may cause the 
occurrence of BC [10, 11]. During the development of 
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BC, estrogen functions as a tumor promotor by acting 
ER which binds to the specific DNA sequences in the 
promoter regions of downstream signaling molecules called 
estrogen response elements (EREs) [12, 13]. Even almost 
all the downstream genes of ER share similar sequences, 
however the transcriptional activation effects differ from 
each other, which causes multitudinous functions of ER in 
BC. Although the carcinogenic role of estrogen in BC has 
been extensively explored in the past, the mechanisms of 
estrogen in BC are not well understood.
microRNAs (miRNAs) are small (approx. 20-22 nt) 
noncoding RNAs which function as post-transcriptional 
regulators by negatively regulating the stability or 
translational efficiency of their target mRNAs [14, 15]. 
In recent years, numerous evidences have shown the vital 
roles of miRNAs in cancer occurrence and development, 
including in BC [16, 17]. For example, miR-21 which 
is overexpressed in multiple cancers and functions as 
an oncogene by targeting different tumor suppressor 
genes, is also upregulated in BC [18–20]. miR-125b is 
downregulated in invasive BC and is associated with 
poor survival rate by regulating its direct target Ets1 in 
BC patients [21, 22]. A few studies indicated miRNAs 
may participate in the carcinogenesis process of estrogen 
induced BC [23], however, little information is known 
about the role and mechanism of miRNAs regulated by 
estrogen and their downstream signaling pathways in BC.
In this study, we found that estrogen upregulated 
and downregulated the expression of certain miRNAs, 
and miR-124 was the most prominent downregulated 
miRNAs in response to estrogen treatment. In this study 
we aim to address the following questions: (1) whether 
estrogen suppresses miR-124 expression through ER, and 
which subunit of ER is required for estrogen-regulated 
miR-124 downregulation; (2)what is the role of miR-124 
in ER positive and ER negative BC cell proliferation, 
migration and invasion with ER treatment; (3) what is/
are functional target(s) of the miR-124; (4) whether the 
target(s) is/are regulated by estrogen in ER positive breast 
cancer cells; and (5) the role of miR-124 in regulating ER 
positive breast tumor growth and angiogenesis. The results 
of this study will shed light on how estrogen regulates 
BC development through regulating miR-124, and will 
be helpful for finding new biomarkers and/or therapeutic 
targets for ER positive BC.
RESULTS
Estradiol (E2) mediates levels of certain 
miRNAs, and miR-124 is the most prominently 
downregulated miRNA which is inhibited by  
E2 treatment in estrogen receptor (ER) positive 
BC cells
Although the carcinogenic effects of estrogen 
in breast tumor are generally accepted, the underlying 
molecular mechanisms remain elucidated. miRNAs are 
demonstratedto play significant roles in cancer occurrence 
and development by inhibiting the expression of their target 
genes at post-transcriptional levels. To explore whether 
estrogen regulates the expression of certain miRNAs in BC, 
the estrogen receptor positive breast cancer cells MCF7 
were treated with 10nM E2 or isopyknic solvent ethyl 
alcohol (Eth) as control for 24h, then the expression levels 
of miRNAs were detected by qRT-PCR. Interestingly, 
several miRNAs were significantly upregulated (miR-196a 
and miR-200a), or downregulated (miR-7, miR-124 
and miR-497) among which miR-124 was the most 
significantly downregulated miRNA (Figure 1A). Thus, we 
will test the role and mechanism of estrogen-suppressed 
miR-124 in BC development in this study. To test whether 
E2 inhibits miR-124 expression through the function of 
ER, the ER-positive and ER-negative BC cells MCF7 and 
MDA-MB-231 were treated with E2 or Eth at different 
time points and the results showed that miR-124 expression 
was downregulated at 6, 12 and 24 h post E2 treatment in 
MCF7 cells (Figure 1B), but not in MDA-MB-231 cells 
(Figure 1C), suggesting that ER is necessary for E2 to 
inhibit miR-124 expression.
ERα, but not ERβ, is required for E2-suppressed 
miR-124 expression
It is well known that ER is composed by two 
subunits ERα and ERβ. To further determine which 
subunit of ER is responsible for the downregulation of 
miR-124 expression, MCF7 cells were transfected with 
siRNAs against ERα, ERβ or negative control (siNC) to 
knock down the expression of ERα and ERβ in the cells, 
respectively. The results showed that the silence of ERα 
significantly inhibited miR-124 expression in a dose-
dependent manner (Figure 2A). However, there was no 
effect of ERβ knockdown on miR-124 expression (Figure 
2B), indicating that ERα, but not ERβ, is involved in 
regulating miR-124 expression. To further confirm the 
role of E2 and ERα in mediating miR-124 expression 
upon E2 treatment, we found that E2 decreased miR-124 
levels in MCF7 cells, whereas the estrogen antagonist 
tamoxifen (TAM) restored miR-124 expression (Figure 
2C). E2 or TAM treatment had no effect on miR-
124 expression in MDA-MB-231 cells (Figure 2D). 
Similarly, knockdown of ERα recovered E2-suppressed 
miR-124 levels in MCF7 cells, but not in MDA-MB-231 
cells (Figure 2E and 2F), demonstrating that miR-124 is 
regulated by E2 via ERα.
Downregulation of endogenous miR-124  
levels promotes cell proliferation, migration  
and invasion
To identify whether endogenous miR-124 affects 
tumor progression, MCF7 and MDA-MB-231 cells were 
transfected with miR-124 inhibitor (Anti-miR-124) or 
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control anti-sense RNA (Anti-miR-NC). Successful 
inhibition of endogenous miR-124 expression was 
confirmed by qRT-PCR (Supplementary Figure 
S1C–S1D). The inhibition of miR-124 remarkably 
increased cell growth, migration, and invasion of the 
breast cancer cells (Figure 3A-3F), demonstrating the 
potential important role of endogenous miR-124 in BC 
development. This result also indicates the downregulation 
of miR-124 induced by estrogen is involved in estrogen-
mediated BC progression.
miR-124 overexpression inhibits E2-induced cell 
proliferation, migration and invasion in  
ER-positive BC cells
To further study the role of miR-124 in E2-
promoted BC development, MCF7 and MDA-MB-231 
cells were transduced by lentivirus carrying miR-124 
or negative control (miR-NC), and the stable cell lines 
were obtained by puromycin selection. We found that 
E2 treatment significantly increased cell proliferation, 
Figure 1: Estradiol (E2) mediates levels of certain miRNAs, and miR-124 is the most prominently downregulated 
miRNA which is inhibited by E2 treatment in estrogen receptor (ER) positive BC cells. A. MCF7, the ER-positive BC cells 
were cultured estrogen-free medium for 72 h, then treated with 10 nM E2 or equal amount of ethyl alcohol (Eth) as solvent control. The 
expression levels of miRNAs were analyzed by qRT-PCR and U6 levels were used as internal control, and normalized to the values of 
Eth control. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. * indicates 
significant difference upon E2 treatment at P < 0.05. B. E2 treatment reduced miR-124 expression in MCF7 cells. Cells were cultured with 
E2 or Eth for 0, 6, 12 and 24 h. The relative miR-124 expression levels were analyzed as above. Data were presented as the means ± SD 
from three independent experiments with triple replicates per experiment. * and ** indicate significant difference under E2 treatment when 
compared to solvent control Eth with P < 0.05 and P < 0.01, respectively. C. E2 treatment had no effect on miR-124 expression in MDA-
MB-231 cells. ER-negative BC cells MDA-MB-231 were treated and miR-124 was detected as above.
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Figure 2: ERα, but not ERβ, was required for E2-suppressed miR-124 expression. A. Knockdown of ERα in MCF7 cells 
induced miR-124 expression. B. ERβ silencing had no effect on miR-124 expression. MCF7 cells were transfected with different dose of 
ERα siRNAs, ERβ siRNAs or negative control siRNAs (siNC). After 72 h, the relative expression levels of miR-124 were analyzed by 
qRT-PCR and normalized to U6 expression levels. Data were presented as the means ± SD from three independent experiments with triple 
replicates per experiment. * and ** indicate significant difference compared to control with P < 0.05 and P < 0.01, respectively. C. E2 
treatment decreased miR-124 expression, which was restored by tamoxifen (TAM) treatment. MCF7 cells were cultured in estrogen-free 
medium and treated without or with 10 nM E2 and 100 nM TAM for 24 h. The expression of miR-124 was detected as above. Data were 
presented as means ± SD from three independent experiments with triple replicates per experiment. ** indicates significant difference 
between two groups at P < 0.01. D. E2 and TAM had no effect on miR-124 expression. MDA-MB-231 cells were treated and miR-124 was 
analyzed as above. E. Knockdown of ERα recovered E2-suppressed miR-124 levels in MCF7 cells. MCF7 cells were cultured as above, 
then transfected with siERα or siNC for 24 h. Cells were treated with or without 10 nM E2 for 24 h and the expression of miR-124 were 
detected as above. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. ** 
indicates significant difference between two groups at P < 0.01. F. E2 treatment and knockdown of ERα showed no effect on miR-124 
expression in MDA-MB-231 cells.
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Figure 3: Downregulation of endogenous miR-124 promotes the proliferation, migration and invasion of BC cells. A. 
and B. MCF7 and MDA-MB-231 cells were transfected with anti-miR-124 inhibitor (Anti-miR-124), or control anti-sense RNA (anti-
miR-NC). Cell Counting Kit-8 (CCK-8) was used to detect cell vitality every 24 h, and the results were presented as the means± SD from 
three independent experiments performed in quintuple. * and ** indicate significant difference compared to anti-miR-NC with P < 0.05 
and P < 0.01, respectively. C. and D. The treated cells were used to perform wound healing assay to estimate the ability of cell migration. A 
sterile 10 μl pipette tip was used to scratch the cells to form a wound when the different treated cells were cultured to 90% confluence. The 
wound gaps were photographed (top) and measured (bottom). Data were presented as the means±SD. ** indicates significant difference 
between two groups at P < 0.01 E. and F. The cells above were used to perform Matrigel invasion assay as described. After incubation 
for 24 h, the cells in the bottom of the invasion chamber were photographed and the acetic acid-eluted solution was quantified using a 
standard microplate reader at 570 nm. Data were presented as the means ± SD from three independent experiments with triple replicates per 
experiment. ** indicates significant difference between two groups at P < 0.01. 
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whereas forced expression of miR-124 attenuated E2-
induced cell proliferation in MCF7 cells. In addition, miR-
124 overexpression also decreased cell growth without 
E2 treatment (Figure 4A). Similarly, forced expression 
of miR-124 markedly suppressed E2 treatment-promoted 
cell migration and invasion in MCF7, the ER-positive BC 
cells (Figure 4C and 4E). On the contrary, E2 treatment 
had no effect on cell proliferation, migration and invasion 
in MDA-MB-231, the ER-negative BC cells. However, 
overexpression of miR-124 attenuated cell proliferation, 
migration and invasion when compared to miR-NC group 
in MDA-MB-231 cells (Figure 4B, 4D and 4F). These 
results show that miR-124 acts as a tumor suppressor 
toinhibittumor development by attenuating cell viability, 
migration and invasion in both ERα-positive and ERα-
negative BC cells. More importantly, miR-124 plays an 
important role in ERα-positive BC cells to suppress the 
estrogen-induced cell viability, migration and invasion, 
demonstrating a novel role of miR-124 in E2-regulated BC, 
which accounts for about 75% of diagnosed breast tumors.
miR-124 directly targets and inhibits AKT2 
expression, miR-124 levels inversely correlates 
with AKT2 expression levels in ERα-positive  
BC tissues
To fully understand the mechanisms of miR-124 
in suppressing E2 induced BC development, TargetScan 
search program was used to predict the targets of miR-
124. We found AKT2, a well-known oncogene, could be 
a potential target of miR-124. The putative binding sites 
between miR-124 and 3’-UTR of miR-124 were shown in 
Figure 4A. To explore whether miR-124 directly targets 
the 3’-UTR of AKT2, we constructed luciferase reporter 
plasmids containing the putative wild-type binding 
sites (WT) and seed sequence mutant sites (mut) at 3’-
UTR of AKT2 (Figure 5A) and verified by sequencing. 
Overexpression of miR-124 in MDA-MB-231 cells 
decreased luciferase activity of wild type reporter to 
50%, suggesting that miR-124 may inhibit the 3’-UTR 
function of AKT2. To test whether miR-124 specifically 
inhibits AKT2 by binding its seed sequence, we also 
mutated the miR-124 binding site in the reporter construct 
(Mutant). Forced expression of miR-124 did not affect 
the transcriptional activation of mutant AKT2 3’-UTR 
(Figure 5B). In addition, stable cells of MCF7 and MDA-
MB-231 overexpressing miR-124 showed decreased 
AKT2 expression at protein level (Figure 5C). These 
results indicate that AKT2 is a direct target of miR-124 by 
binding to the seed sequence. Furthermore, Spearman’s 
rank correlation analysis showed an inverse correlation 
between expression levels of AKT2 and miR-124 in 
human BC specimens (Spearman’s correlation r=-0.3130, 
Figure 5D). These results show the negative correlation 
between the expression levels of miR-124 and its target 
AKT in human BC tissues.
Next, to determine the expression levels of AKT2 in 
clinical BC specimens and adjacent normal tissues, qRT-
PCR assay was performed to detect AKT2 expression 
levels in tissues, then analyzed by densitometric 
measurement and normalized to the GAPDH expression 
levels. Compared to the adjacent normal tissues, BC 
tissues (n = 46) showed significantly higher levels 
of AKT2 (P < 0.01, Figure 5E). And for the first time, 
we found that ERα-positive BC tissues showed higher 
AKT2 expression levels than ERα-negative BC tissues 
(P < 0.05, Figure 5F), suggesting that AKT2 may be a 
potential biomarker for BC detection and has significance 
to differentiate ERα-positive BC in clinical tissue samples.
Forced expression of AKT2 reverses  
miR-124-suppressed cell proliferation, migration 
and invasion
To determine whether miR-124 inhibits BC 
development through its target AKT2, the stable cells of 
MCF7 and MDA-MB-231 cells overexpressing miR-124 
were transfected with AKT2 cDNA without 3’-UTR. The 
immunoblotting results confirmed the effect of AKT2 
cDNA transfection (Figure 6A and 6B). Overexpression 
of AKT2 was sufficient to reverse miR-124-inhibited 
cell proliferation, migration and invasion in both MCF7 
(Figure 6C, 6E and 6G) and MDA-MB-231 cells (Figure 
6D, 6F and 6H), suggesting that the inhibitory effect of 
miR-124 in human BC cells is via the function of its 
target AKT2.
ERα is required for E2 upregulated-AKT2 
expression, which can be inhibited by miR-124  
in ERα-positive BC cells
Our previous results demonstrate that E2 regulates 
miR-124 expression in ERα-positive cells, but not in 
ERα-negative cells. To further study whether E2 affects 
expression levels of AKT2, the target of miR-124, we 
found that E2 treatment promoted AKT2 expression in 
MCF7 cells (Figure 7A), but not in MDA-MB-231 cells 
(Figure 7B). E2 treatment induced AKT2 expression to 
4.5-fold, whereas TAM treatment decreased E2-induced 
AKT2 levels by 50% which was still higher than that in 
cells without E2 treatment (Figure 7C). On the contrary, 
E2 and TAM showed no effect on AKT2 expression 
in MDA-MB-231 cells, which is consistent with our 
previous results showing that E2 and TAM did not 
regulate miR-124 levels in MDA-MB-231 cells (Figure 
7D). Furthermore, without E2 treatment, knockdown 
of ERα significantly increased AKT2 expression levels 
(P < 0.05) in MCF7 cells. Although the expression 
levels of AKT2 are higher in MCF7 cells under the 
treatment of E2 combination with ERα knockdown 
when compared to the cells ERα knockdown without 
E2 treatment, ERα is necessary for E2-induced AKT2 
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Figure 4: miR-124 overexpression inhibits E2-induced cell proliferation, migration and invasion in ER-positive BC 
cells. The estrogen-positive and -negative cell lines MCF7 and MDA-MB-231 were infected with lentivirus carrying miR-124 or miR-NC 
to establish stable cell lines. A. MCF7/miR-124 and MCF7/miR-NC stable cells were plated at 2,000 cells/well in 96-well plates. After 
adherence, cells were treated with E2 or Eth solvent. Cell Counting Kit-8 (CCK-8) was used to detect cell vitality every 24 h and the results 
were presented as the means± SD from three independent experiments performed in quintuple. * and ** indicate significant difference 
compared to miR-NC without E2 treatment group with P < 0.05 and P < 0.01, respectively; # and ## indicate significant difference upon E2 
treatment with P < 0.05 and P < 0.01, respectively; & and && indicate significant difference when compared to miR-NC with E2 treatment 
group with P < 0.05 and P < 0.01, respectively. B. MDA-MB-231/miR-124 and MDA-MB-231/miR-NC stable cells were treated and 
analyzed as above. ** indicates significant difference compared to miR-NC without E2 treatment group at P < 0.01. C. and D. The stable 
cells above with or without E2 treatment were used to perform wound healing assay to estimate the ability of cell migration. A sterile 10 
μl pipette tip was used to scratch the cells to form a wound when the different treated cells were cultured to 90% confluence. The wound 
gaps were photographed (top) and measured (bottom). Data were presented as the means± SD. * and ** indicate significant difference 
between two groups with P < 0.05 and P < 0.01, respectively. E. and F. The stable cells above were used to perform Matrigel invasion 
assay as described. In addition, the E2 or Eth solvent was mixed into the medium respectively in the lower chamber. After incubation 
for 24 h, the cells in the bottom of the invasion chamber were photographed and the acetic acid-eluted solution was quantified using a 
standard microplate reader at 570 nm. Data were presented as the means ± SD from three independent experiments with triple replicates per 
experiment. * and ** indicate significant difference between two groups with P < 0.05 and P < 0.01, respectively. 
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expression. However, neither E2 treatment nor ERα 
knockdown showed effect on AKT2 expression in 
MDA-MB-231 cells (Figure 7E and 7F). Although 
E2 treatment significantly induced AKT2 expression 
in MCF7 cells, but not in MDA-MB-231 cells, forced 
expression of miR-124 suppressed AKT2 expression 
with or without E2 treatment in both cells (Figure 7G–
7J). In addition, silence of miR-124 by siRNAs reversed 
the AKT2 suppression caused by the interference of 
ERα in ER positive BC cells, and our result indicated 
high correlation between ERα and AKT2 levels via 
miR-124 levels (Figure 7K–7M).
Overexpression of miR-124 inhibits tumor 
growth and angiogenesis
Finally, to further investigate the role of miR-124 
in breast tumor growth and angiogenesis in vivo, ectopic 
Figure 5: miR-124 directly targets and inhibits AKT2 expression, miR-124 levels inversely correlates with AKT2 
expression levels in ERα-positive BC tissues. A. Putative seed-matching sites (in bold) or mutant sites (red) between miR-124 
and 3’-UTR of AKT2. B. Luciferase reporter assay was performed using MDA-MB-231 cells to detect the relative luciferase activities of 
WT and mut AKT2 reporters. Renilla luciferase vector was used as an internal control. Data were presented as the means± SD from three 
independent experiments with triple replicates per experiment. ** indicates significant difference compared to control at P < 0.01. C. The 
expression of AKT2 and GAPDH was determined using immunoblotting in MCF7 and MDA-MB-231 cells overexpressing miR-124 and 
miR-NC. The densities of AKT2 were quantified by ImageJ software and GAPDH levels were used as internal control, and normalized to 
the values of Eth control. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. 
** indicates significant difference compared to control at P < 0.01. D. Spearman’s correlation analysis was used to determine the correlation 
between the expression levels of AKT2 and miR-124 in human BC specimens (n=46). Data were presented as the means ± SD from three 
independent experiments with triple replicates per experiment. E. The expression levels of AKT2 in adjacent normal tissues and human 
BC specimens were determined by qRT-PCR, and the fold changes were obtained from the ratio of AKT2 to GAPDH levels. Data were 
presented as mean from three independent experiments with triple replicates per experiment. ** indicates significant difference comparing 
normal tissues at P < 0.01. F. The relative AKT2 expression levels of BC tumors were analyzed according to ERα status (ERα-negative, 
n=17; ERα–positive, n =29). Data were presented as mean from three independent experiments with triple replicates per experiment. * 
indicates significant difference comparing ERα-negative and ERα–positive tumors at P < 0.05.
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Figure 6: Forced expression of AKT2 reverses miR-124-suppressed cell proliferation, migration and invasion. miR-
124- or miR-NC-overexpressing cells were transfected with vector or AKT2 cDNA without 3’-UTR. A. and B. The expression levels 
of AKT2 and GAPDH were determined by immunoblotting after 48 h. C. and D. Cell viability was detected using CCK-8 assay. Data 
were presented as the means ± SD from three independent experiments with triple replicates per experiment. * and ** indicate significant 
difference compared to miR-NC+vector group with P < 0.05 and P < 0.01, respectively. # and ## indicate significant difference compared 
to miR-124+vector group with P < 0.05 and P < 0.01, respectively. E. and F. Cells were treated and wound healing assay was performed 
as above. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. ** indicates 
significant difference compared to miR-NC+vector group at P < 0.01; ## indicates significant difference compared to miR-124+vector 
group at P < 0.01. G. and H. Transwell invasion assay was performed as above using control cells and cells overexpressing miR-124 with 
or without AKT2 overexpression. Data were presented as the means ± SD from three independent experiments with triple replicates per 
experiment. ** indicates significant difference compared to miR-NC+vector group at P < 0.01; ## indicates significant difference compared 
to miR-124+vector group at P < 0.01. 
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Figure 7: ERα is required for E2 upregulated-AKT2 expression, which can be inhibited by miR-124 in ERα-positive 
BC cells. A. and B. MCF7 and MDA-MB-231 cells were cultured as above and treated with E2 for 0, 6, 12 and 24 h. The relative AKT2 
expression of each group was analyzed by qRT-PCR and represented the ratio to control group. Data were presented as the means ± SD from 
three independent experiments with triple replicates per experiment. ** indicates significant difference compared to control at P < 0.01. 
C. and D. TAM was used as the E2 antagonist and the expression levels of AKT2 were analyzed by qRT-PCR. Data were presented as the 
means ± SD from three independent experiments with triple replicates per experiment. * and ** indicate significant difference between two 
groups with P < 0.05 and P < 0.01, respectively. E. and F. Cells were cultured and treated as in Figure 2E, the expression levels of AKT2 
were analyzed as above. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. 
** indicates significant difference between two groups at P < 0.01. G. and H. The cells were cultured as above and the expression levels of 
AKT2 were determined by qRT-PCR in miR-124- and miR-NC-overexpressing cells without or with E2 treatment for 24 h using GAPDH 
levels as internal control, and normalized to the value of Eth control. Data were presented as the means ± SD from three independent 
experiments with triple replicates per experiment. * and ** indicate significant differences between two groups with P < 0.05 and P < 
0.01, respectively. I. and J. The expression levels of AKT2 and GAPDH were determined by immunoblotting in miR-124- and miR-NC-
overexpressing cells without or with E2 treatment for 48 h. The densities of AKT2 were quantified by Image J software and GAPDH levels 
were used as internal control, and normalized to the values of Eth control. Data were presented as the means ± SD from three independent 
experiments with triple replicates per experiment. * and ** indicate significant differences between two groups with P < 0.05 and P < 0.01, 
respectively. K. and L. MCF7 and MDA-MB-231 cells were cultured as above and transfected with siRNAs, and divided in four groups 
including siNC+Anti-miR-NC, siERα+Anti-miR-NC, siNC+Anti-miR-124, siERα+ Anti-miR-124 group. After 24 h, the expression levels 
of AKT2 were determined by qRT-PCR using GAPDH levels as internal control, and normalized to the values of siNC+Anti-miR-NC 
group. Data were presented as the means ± SD from three independent experiments with triple replicates per experiment. ** indicates 
significant difference between two groups at P < 0.01 M. and N. Cells were cultured as above and transfected with Anti-miR-NC or Anti-
miR-124. After 24 h, the cells were treated with or without 10 nM E2 and 100nM TAM for 24 h. The expression levels of AKT2 were 
determined by qRT-PCR using GAPDH levels as internal control, and normalized to the values of Eth+Anti-miR-NC group. Data were 
presented as the means ± SD from three independent experiments with triple replicates per experiment. ** indicates significant difference 
between two groups at P < 0.01.
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transplantation model of human BC in nude mice was 
employed.MCF7 cells overexpressing miR-124 or miR-
NC were subcutaneously injected into both posterior 
flanks of nude mice. Tumor volumes were monitored 
every two days when they were palpable during the 
tumor inoculation period.Compared to miR-124 group, 
the tumor size of miR-NC group was significantly 
increased by Day 11 (P < 0.05) and grew more and more 
quickly (Figure 8A). Nude mice were sacrificed 17 days 
after implantation and xenografts were trimmed out. The 
tumor size of miR-124 group was smaller than that of 
control group (Figure 8C). Consistent with tumor size, 
the tumor weight of miR-124 group was 31% of control 
group (Figure 8B).
Moreover, tumors from MCF7/miR-124 group 
showed decreased number of microvessels with CD31 
positive staining by 68% when compared to control 
group (Figure 8D). In agreement with the results in vitro, 
overexpression of miR-124 suppressed AKT2 expression, 
in tumor tissues (Figure 8E). These results suggest that 
miR-124 suppresses tumorigenesis and angiogenesis of 
human ERα-positive BC in nude mice, and AKT2 is an 
important target involved in this process.
DISCUSSION
Estrogen has been reported to play an important 
role in tumor occurrence and development during 
the past several decades [24]. Estrogen always acts 
as a carcinogenic factor by multiple aspects such as 
promoting cell proliferation, metastasis and drug-
resistance of BC cells [3]. The effects of estrogen 
Figure 8: Overexpression of miR-124 inhibits tumor growth and angiogenesis. A. MCF7/miR-124 and MCF7/miR-NC cells 
were dispersed in 100 μl of serum-free DMEM medium and were subcutaneously injected into both sides of posterior flank of the nude 
mice (n=4). Tumors were measured every two days since they were apparently seen and the volumes were calculated using the following 
formula: volume = 0.5 × Length × Width2. * and ** indicate significant difference compared to miR-NC group with P < 0.05 and P < 
0.01, respectively. B. The tumor was excised and weighed after 17 days. Data were presented as the means ± SD. ** indicates significant 
difference compared to miR-NC group at P < 0.01. C. The representative pictures of trimmed tumors (Bar= 10mm). D. The expression 
levels of CD31 were analyzed in tumor tissues by immunohistochemistry. The density of CD31 levels was quantified by ImageJ software. 
Magnification, ×200, Scale bar, 20 μm. E. The whole protein was extracted from xenografts and subjected to immunoblotting assay for 
AKT2 expression. GAPDH expression was served as an internal control.
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in BC have been widely studied; however, the 
underlying molecular mechanisms of estrogen in BC 
are still unclear. miRNAs are endogenous small non-
coding RNAs, and play critical roles in cell growth, 
differentiation, apoptosis and tumourigenesis by 
negative regulating the mRNAs of oncogenes or tumor-
suppressor genes [25, 26]. Some studies indicatethat 
miRNAs may play important roles in estrogen 
induced BC [27, 28]. It was showed that miR-515-
5p was downregulated by estrogen treatment in ER 
positive BC cells to regulate the BC cell proliferation 
through its target SK1 [1]. ERα upregulated c-Myc 
expression which can downregulate ERα as a negative 
autoregulatory feedback loop [29]. However, there 
is still lack of the knowledge about the roles of 
estrogen-regulated miRNAs in BC development. In 
this study, we demonstrated that E2 could upregulate 
or downregulate certain miRNAs, and miR-124 was 
the most prominently downregulated miRNA which 
is regulated by E2 treatment in ER-positive BC cells. 
miR-124 has been reported to act as a tumor suppresser 
in many cancers including BC [30–32]. In this study, 
we discovered that estrogen-regulated miR-124 plays 
an important role in BC cell proliferation, migration, 
invasion, tumor growth and angiogenesis, and also 
identified that miR-124 suppression caused by E2 
in ER-positive BC cells is through ERα instead of 
ERβ. Some reports indicated that ERα instead of ERβ 
interacts with and suppresses Drosha activity through 
which could downregulate numbers of miRNAs in ER-
positive BC cells that were similar to our data [33], 
however, the in-depth mechanisms of downregulation of 
miR-124 induced by estrogen remains to be elucidated.
Our previous studies have showed that miR-124 
could govern glioma growth and angiogenesis and enhance 
chemosensitivity by targeting R-Ras and N-Ras [34]. It was 
also reported that miR-124 inhibited cellular proliferation 
and invasion by targeting Ets-1 in breast cancer cells [35]. 
Although there were several identified targets of miR-124 
which participated in miR-124 mediated BC development 
and progression, the researches about the functions and 
mechanisms of estrogen downregulated miR-124 in ER 
positive BC cells are still scanty. It has been reported that 
the activated AKT2 phosphorylates ERα and promotes the 
transcriptional activity of ERα [36, 37]. Interestingly, ERα 
can also activate AKT2 although the underlined mechanism 
is still unknown [36]. There is a correlation between ERα 
and AKT2. AKT2 (v-AKT murine thymoma viral oncogene 
homologue 2), an isoform of AKT family, is a significant 
member of the the PI3K/AKT pathway [38, 39]. Increasing 
studies demonstrate the important role of AKT2 in cancers 
as an oncogene [40] which is closely associated to tumor 
aggressiveness by enhancing the survival, migration and 
invasion of cancer cells primarily [36, 41], and overexpress 
in many human tumors including BC and ovarian cancer 
[42]. In this study, we discovered that AKT2 was a new 
direct target of miR-124, which was confirmed by clinical 
BC specimens showing that miR-124 levels inversely 
correlate with AKT2 expression levels. AKT2 was shown 
to be upregulated in ERα-positive BC tissues. miR-124 
may act as a tumor suppressor to inhibit BC development 
by targeting AKT2, and ERα is required for E2 upregulated-
AKT2 expression, which can bereversedby miR-124 in ERα-
positive BC cells. Our results demonstrate a key role of a new 
regulatory circuitof E2/ERα/miR-124/AKT2 in mediating 
tumor angiogenesis and cancer progression in BC.
In summary, we have demonstrated that miR-124 is 
one of the miRNAs which are regulated by estrogen levels. 
The downregulation of miR-124 by E2 in ER-positive BC 
cells is through ERα but not ERβ, which will broaden our 
understanding the mechanisms of estrogen-modulated BC. 
Besides, we identified AKT2 as a novel target of miR-124, 
which is upregulated in clinical BC specimens, which may 
be used to differentiate ERα-positive and –negative BC. 
Similar to E2-downregulated miR-124, E2 induces AKT2 
expression through ERα. The new regulatory circuit of 
E2/ERα/miR-124/AKT2 in BC plays an important role in 
BC tumorigenesis and development, which will provide 
potential novel biomarkers and targets for the diagnosis 
and treatment of BC.
MATERIALS AND METHODS
Human tissue samples
Human BC samples and adjacent normal tissues 
were obtained from patients in the First affiliated hospital 
of Anhui Medical University, Hefei, China and the Huai’an 
First People’s Hospital, Nanjing Medical University. 
Tissue samples were collected at surgery, immediately 
frozen in liquid nitrogen and stored until total RNAs or 
proteins were extracted. All experiments were approved 
by the ethics committee of Anhui Medical University and 
Nanjing Medical University.
Cell culture
BC cell lines MCF7 and MDA-MB-231 were 
maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum 
(FBS), 100 units of penicillin/mL and 100 ng of 
streptomycin/mL. Human embryonic kidney 293T(HEK-
293T) cells were cultured in DMEM supplemented with 
10% FBS, penicillin(100U/ml), streptomycin(100ng/ml) 
and 2 mmol/mL glutamine. All cell lines were maintained 
in a 37°C incubator with 5% CO
2
.Before treatment with 
estradiol (17β-estradiol, E2; Sigma-Aldrich Ltd.), ethanol 
solvent (Eth, used as negative control), or tamoxifen 
(Sigma), cells were maintained for 3 days in DMEM 
without phenol red (Gibco) supplemented with 10% 
double charcoal–stripped FCS (Gibco) and pen/strep 
at 37°C with 5% CO
2
. On the day of treatment, media 
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was changed to DMEM without phenol red (Gibco) 
supplemented with 10% FCS (Gibco) and 100 U/mL 
penicillin and 100 ng/mL streptomycin.
Lentiviral packaging and stable cell line 
establishment
The lentiviral packaging kit was purchased from 
Open Biosystems (Huntsville). Lentivirus carrying 
miR-124 or negative control (miR-NC) was packaged in 
293T cells and collected from the supernatant as instructed 
by the manufacturer’s manual.The lentiviruses were 
infected into MCF7 or MDA-MB-231 cells to establish 
stable cell lines,followed by puromycin selection.
Isolation of RNA, reverse transcription PCR and 
quantitative real-time PCR
Total RNA was isolated from cultured cells or human 
tissues with TRIzol reagent according to the manufacturer’s 
instruction (Invitrogen). To determine the quantity of the 
mRNA levels of AKT2, total RNAs were reverse transcribed 
by oligodeoxythymidine primer using the PrimeScript RT 
Reagent Kit. The housekeeping gene GAPDH was used as an 
internal control. The primers were as follows: AKT2 forward 
primer, 5’- ACCACAGTCATCGAGAGGACC -3′;AK 
T2 reverse primer, 5′-GGAGCCACACTTGTAGTCCA-3′; 
GAPDH forward primer, 5′-CCACCCATGGCAAATTCC 
ATGGCA-3′; GAPDH reverse primer, 5′-TCTAGACGGCA 
GGTCAGGTCCACC-3′. To measure the expression levels 
of miR-124, the stem-loop specific primer method was 
used as described previously [43, 44]. Quantitative reverse 
transcriptase (qRT) PCR primers were the following: miR-
124 RT primer, 5′- CTCAACTGGTGTCGTGGAGTC
GGCAATTCAGTTGAGGGCATTC-3′; miR-124 PCR 
primers, sense: 5′-ACACTCCAGCTGGGTAAGGCACG
CGGTG-3′; antisense: 5′-TGGTGTCGTGGAGTCG-3′. 
U6 RT primer: 5′-AACGCTTCACGAATTTGCGT-3′; U6 
PCR primers, sense: 5′-CTCGCTTCGGCAGCACA-3′; 
antisense: 5′-TGGTGTCGTGGAGTCG-3′.Quantitative 
RT-PCR was performed using SYBR Premix Dimer Eraser 
(Vazyme Biotech co.,ltd) on a 7900HT system. GAPDH or 
U6 levels were used as an internal control, and fold changes 
were calculated by relative quantification (2–ΔΔCt).
Luciferase reporter assay
The 3’-UTR-luciferase reporter constructs 
containing the 3’-UTR of AKT2 with wild-type and 
mutant binding sites of miR-124 were amplified using 
PCR method. The PCR products were cloned into the 
pMiR-luc reporter vector (Ambion) between SpeI and 
HindIII sites, immediately downstream of the luciferase 
gene. The mutant 3’-UTR constructs were made by 
introducing four mismatch mutations into the putative 
seed regions of AKT2. All the constructs containing 
3’UTR inserts were sequenced and verified.
MDA-MB-231 cells (1.0×105/well) were seeded in 
24-well plates. After 24 h, cells were co-transfected with 
either wild-type (WT) or mutant-type (mut) luciferase 
reporter plasmids containing AKT2-3’-UTR, pGL4.74 
vector control (Ambion) and equal amounts of pre-
miR-124 or pre-miR-NC using Lipofectamine 2000 
(Invitrogen) according the manufacturer’s instruction. 
Luciferase activities were measured 24 h after transfection 
using the Dual Luciferase Reporter Assay System 
(Promega). Experiments were performed in triplicate with 
three independent replicates.
Protein extraction and immunoblotting
Cells or tissues grounded in liquid nitrogen were 
lysed on ice for 30 min in radioimmunoprecipitation assay 
(RIPA) buffer (150 mM NaCl, 100 mM Tris, pH 8.0, 0.1% 
sodium dodecyl sulfate (SDS), 1% Triton X-100, 1% 
sodium deoxycholate, 5 mM EDTA, and 10 mM NaF) 
supplemented with 1 mM sodium vanadate, 2 mM aprotinin, 
2 mM leupeptin, 1 mM phenylmethylsulfonyl fluoride, 
1 mM dithiothreitol, and 2 mM pepstatin A. The lysates 
were centrifugated at 12,000 rpm at 4°C for 15 min, the 
supernatants were collected, and protein concentrations were 
determined using bicinchoninic acid assay. Protein extracts 
were separated by SDS–polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membranes in transfer 
buffer (20 mM Tris, 150 mM glycine, 20% [volume/volume] 
methanol). Membranes were blocked with 5% nonfat dry 
milk for 2 h and incubated with primary antibodies (AKT2, 
Proteintech; GAPDH, Abcam). The protein bands were 
probed with secondary antibody, and visualized with the elec
trochemiluminescencedetection system (Thermo Scientific).
Cell proliferation assay
Cells in the logarithmic phase of growth were 
seeded at 3,000/well and cultured in 96-well plates. 
Cell proliferation was assayed using the Cell-Counting 
Kit 8 (CCK8; Dojindo Laboratories) according to the 
manufacturer’s instructions at indicated time points. 
Three independent experiments were performed in 
triplicate.
Wound healing assay
Cells were cultured until reached 90% confluence 
in 6-well plates. Cell layers were scratched using a 10 
μL tip to form wounded gaps, washed with PBS twice 
and cultured. The wounded gaps were photographed 
at different time points and analyzed by measuring the 
distance of migrating cells from five different areas for 
each wound.
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Invasion assays
Cell invasion was determined using 24-well 
invasion chambers with Matrigel (Becton Dickinson) 
according to the manufacturer’s instructions. Cells 
(5×104/well) were seeded in the upper well of the invasion 
chamber in DMEM without serum. The lower chamber 
well contained DMEM supplemented with 10% FBS to 
stimulate cell invasion. After incubation for 24 h, non-
invading cells were removed from the top well with a 
cotton swab, while the bottom cells were fixed with 3% 
paraformaldehyde, stained with 0.1% crystal violet, and 
photographed in 3 independent 10× fields for each well. 
Membrane was air-dried and soaked for 15 min at room 
temperature with 33% acetic acid decolorization (200 μL/
well). The destained solution was transferred to 96-well 
plates, and the absorbance value was read at an optical 
density of 570 nm. Three independent experiments were 
conducted in triplicate.
Tumorigenesis in nude mice
For tumor growth assay, female nude mice 
[BALB/cA-nu (nu/nu), 6-wk-old] were purchased from 
Shanghai Laboratory Animal Center (Chinese Academy 
of Sciences) and maintained in special pathogen-free 
(SPF) condition for one week. Animal protocols 
were approved by the Animal Experimental Ethics 
Committee of Nanjing Medical University. MCF7 cells 
stably expressing miR-124 or miR-NC were injected 
subcutaneously into both flanks of nude mice (5×106 cells 
in 100 μl serum-free DMEM medium). Tumor sizes were 
measured using vernier caliper every two days when the 
tumors were visible and tumor volume was calculated 
according to the formula: volume = 0.5×Length×Width2. 
Mice were sacrificed and tumors were dissected 17 
days after implantation. Total proteins and RNAs were 
extracted for immunoblotting and qRT-PCR. Tumors 
were formalin-fixed, paraffin-embedded, and sectioned at 
5μm for CD31 (Abcam) immunohistochemical staining 
under the standard procedure as previously described 
[45].
Statistical analysis
Data in the present study were represented as 
means ± SD from at least three independent experiments 
except specific indicated. Student’s unpaired t test was 
used for comparison between two groups.Data were 
analyzed with GraphPad Prism 5(La Jolla, CA, USA). 
For human tissue samples, AKT2 expression levels 
in adjacent normal and BC tissues were explored by 
Student’s paired t test. AKT2 levels in ERα-positive and 
negative groups were analyzed using Student’s unpaired 
t test. Values were considered significantly different 
when P < 0.05.
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